

HIMSS

& Southern Ohio Chapter

Shifting to Fee for Value: The Information Mandate

Randy L. Thomas, FHIMSS

Service Line Executive

Bryan Eckert

Strategic Advisor

CSOHIMSS 2013 Spring Conference May 17, 2013


Discussion Topics



What is the "information mandate" and why do it?

- How does it work?
- What will it take to be successful?
- Case study the journey of one organization

New Models Require New Capabilities



Himss


Central & Southern Ohio Chapter

Hardwiring Performance to Payment

Clinically Integrated Networks

Patient Centered Medical Home






- ✓ Shared Savings
 - ✓ Readmission penalties
 - ✓ Incentive based payments

 \checkmark

Transforming How Quality and Performance Will be Measured




Himss

entral & Southern Ohio Chapter

Measuring





"If you can't measure it, you can't improve it"

Lord Kelvin (Sir William Thomson)

Federal (and Commercial) Contracts are Driving Requirements



Himss

Central & Southern Ohio Chapter

http://www.ofr.gov/OFRUpload/OFRData/2013-10234_PI.pdf

I

eMeasures: Based on Evidencebased Guidelines and Programs



Get with the Guidelines: Stroke





Measure Process Performance



- Percent of acute ischemic stroke patients who arrive at the ED at the hospital within 120 minutes (two hours) of onset of stroke symptoms who receive IV t-PA within 180 minutes (three hours) of onset of stroke symptoms
- Percent of ischemic stroke or TIA patients who receive antithrombotic medication within 48 hours of hospitalization
- Percent of ischemic stroke or TIA patients discharged on antithrombotics (e.g., warfarin, aspirin, other antiplatelet drug)
- Percent of ischemic stroke or TIA patients with atrial fibrillation who are discharged on anticoagulation therapy (warfarin/Coumadin or heparin/heparinoids) unless an absolute or relative contraindication exist
- Percent of patients at risk for DVT who received DVT prophylaxis by the second hospital day
- Percent of ischemic stroke or TIA patients with LDL > or = 100 mg/dL OR on cholesterol reducer prior to admission who are discharged on cholesterol-reducing drugs
- Percent of smokers who receive smoking cessation advice or medication (e.g., Nicoderm or Zyban) at discharge

eMeasures & Analytics Start in the EHR: Getting the Data Right





NUMERATOR

1011100011

All ischemic stroke patients prescribed anti-thrombotic therapy at hospital discharge.

All ischemic stroke patients excluding (age < 18, LOS > 120 days, transfer patients, expired patients, patients in clinical trials, elective patients, patients with comfort measures).

1001110011

DENOMINATOR


Build for computerization using standards set by the NQF and CMS

- Definition of ischemic stroke value set (61 SNOMED CT codes)
- Definition of medication value set (105 RX Norm codes)
- Exclusion criteria require:
 - 21 Elements
 - 19 Code tables (SNOMED, NUBC, RxNorm)
 - 281 Individual codes

Workflows & Data Needs are Interdependent




Identifying Stroke 2 patients impacts physician workflow before discharge...



Technology & Tools





Knowledge & Insights



Community Medical Grou		<u> </u>											
	Cardiovascular	Rate											
Currently viewing:	Annual Monitoring for Patients on Persistent Medications-ACEI/ARB, Digoxin, Diuretics **	-											
	Cholesterol Management-LDL Screening	-											
Seaside Clinic	Cholesterol Management-LDL Control <100	-											
	HF: LVEF Assessment (Outpatient setting)	-											
	HF: Symptom and Activity Assessment	-											
iew	HF: Beta-blocker Therapy for LVSD **	-											
stem	HF: ACE Inhibitor or ARB Therapy for LVSD **	-											
nic	HF: Congestive Heart Failure Admission Rate	-											
ysician	HF: Post-discharge Appointments for HF Patients	-											
	HF: Hospital 30-day, all-cause, risk-standardized readmission rate following heart failure hosp.	-											
easure Domains	Diabetes	Rate											
	HbA1c Testing **	-											
nical	HbA1Cc Poor Control >9.0% **	-											
aningful Use of Health IT	HbA1c Control <8.0% **	-											
tient Experience	HbA1c Control <7.0% **	-	Overview	1	Meaningful U	se-EH	Meaning	ful Use - EP	Interna	al Measureme Analysis	ent &	Clinical Analyti Care Coordina	
propriate Resource Use	LDL Screening **	-								Analysis		Care Coordina	atio
her Measures	LDL Control <100 **	-											
	Nephropathy Monitoring	-	Demo	_									
						an Mana	anmor	nt _ Haa	et Eailur	o "Uudd		shoard	
roviders	Blood Pressure Control <140/90 **	-	ional Ha	_{with} P	opulatio	on wana	iyemer	n – nea	rt Fallur	епиии	le" Das	ibuaru	
	Blood Pressure Control <140/90 **	-	ional He	alth P	opulatio	on wana	igemei	n – nea	IT Failur	епици	ie" Das	iboaru	
ames Messink, MD			ional He System	alth P	opulatio	on wana	igemei	n – 11ea	int Failur	e nuuu	le" Das	iboaru	
ames Messink, MD obert Boyne, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention	_ Rate		alth P	opulatio	on wana	igemer	n-116a	int Failui	e nuuu	ie" Das	iboaru	
ames Messink, MD obert Boyne, MD eter Broxon, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens **	_ Rate _				ents – John C	Ĵ	n-nea	iit Fallui	e nuuu	ie" Das	iboaru	
ames Messink, MD obert Boyne, MD eter Broxon, MD ohn Casada, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal **	Rate –	System		ODAY's Patie		asada, MD	n – 116a	labs	e nuuu	Consult	Hospitalia	izatio
imes Messink, MD obert Boyne, MD eter Broxon, MD ihn Casada, MD sa Gray, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 **	 Rate 	System	s T(Next Veek Patie	ODAY's Patie Disease Stage	ents – John C Vital S Date BP	asada, MD Signs Date Wg	t Date LDL	Labs	K+ Date	Consult Na+ Date /	Hospitali 10 Date	D
imes Messink, MD obert Boyne, MD eter Broxon, MD ohn Casada, MD sa Gray, MD aren Morale, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened **	 Rate 	System	s T(Next Veek Smith	ODAY's Patie Disease ant Stage th, A 3	ents – John C Vital S Date BP 2/12/12 130/74	asada, MD Signs Date Wg 4 2/12/12 12	t Date LDL 0 8/15/11 14	Labs		Consult Na+ Date // 135	Hospitali	D
mes Messink, MD obert Boyne, MD eter Broxon, MD hn Casada, MD sa Gray, MD aren Morale, MD ffery Noggler, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening-Ages 50-69 **	 Rate 	System	3 T(Next Veek Patie Senit Harc	Disease bit Stage th, A 3 dy, J 3 s, B 3	ents – John C Vital 5 Date BP 2/12/12 130/77 12/20/11 90/74	asada, MD Signs Date Wg 4 2/12/12 12 4 12/20/12 9 3/6/12 14	t Date LDL 10 8/15/11 14 12/20/11 13 14 3/6/12 14	Labs L HDL Date 0 60 2/12/20 0 65 12/20/ 0 60 3/6/	K+ Date /12 3.8 2/12/12 /12 3.5 12/20/12 /12 4 3/6/12	Consult Na+ Date / 135 140 135 6/18/12(26	Hospitalia 10 Date 12/20/11Arryth d 12/20/11Acute	D thmia e MI
mes Messink, MD obert Boyne, MD tter Broxon, MD hn Casada, MD sa Gray, MD aren Morale, MD ffery Noggler, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening-Ages 50-69 ** Colorectal Cancer Screening **	 Rate 	System Appointments Tomorrow	s T(Next Veek Patie Smith Hard Kome Hall,	Disease Disease th, A 3 dy, J 3 s, B 3 , C 2	ents – John C Vital 5 Date BP 2/12/12 130/74 12/20/11 90/74 2/5/12 130/74	asada, MD Signs Date Wg 4 2/12/12 12 4 12/20/12 9 4 12/20/12 13 4 2/5/12 13	t Date LDL 10 8/15/11 14 18 12/20/11 13 14 3/6/12 14 8/15/11 14	Labs L HDL Date 0 60 2/12/ 0 65 12/20/ 0 60 2/12/ 0 60 2/12/	/12 3.8 2/12/12	Consult Na+ Date / 135 140 135 6/18/12/20 135	Hospitalii Date 12/20/11Arryth 12/20/11Acute 12/20/11Acute	D thmia <mark>e Mi</mark> te Mi
mes Messink, MD obert Boyne, MD ster Broxon, MD hn Casada, MD sa Gray, MD aren Morale, MD ffery Noggler, MD mothy Shadley, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening-Ages 50-69 **	 Rate 	System Appointment Tomorrow Y S rt Boyne Broxon	s T(Next Veek Patie Smith Hard Kome Hall,	Disease Disease th, A 3 dy, J 3 s, B 3 , C 2	ents – John C Vital 5 Date BP 2/12/12 130/74 12/20/11 90/74 2/5/12 130/74	asada, MD Signs Date Wg 4 2/12/12 12 4 12/20/12 9 4 12/20/12 13 4 2/5/12 13	t Date LDL 10 8/15/11 14 18 12/20/11 13 14 3/6/12 14 8/15/11 14	Labs L HDL Date 0 60 2/12/ 0 65 12/20/ 0 60 2/12/ 0 60 2/12/	K+ Date /12 3.8 2/12/12 /12 3.5 12/20/12 /12 3.8 2/5/12	Consult Na+ Date / 135 140 135 6/18/12/20 135	Hospitalii Date 12/20/11Arryth 12/20/11Acute 12/20/11Acute	D thmia <mark>e Mi</mark> te Mi
imes Messink, MD obert Boyne, MD eter Broxon, MD hn Casada, MD sa Gray, MD aren Morale, MD ffery Noggler, MD imothy Shadley, MD faria Vecchia, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening-Ages 50-69 ** Colorectal Cancer Screening **	 Rate 	System Appointment Tomorrow V HS Rt Boyne Broxon Casada	3 TC Vext Veek Patie Harrison Hall, Mari	Disease Stage ant Stage th, A 3 dy, J 3 ss, B 3 c, C 2 *, D 4	ents – John C Vital 5 Date BP 2/12/12 130/74 12/20/11 90/74 2/5/12 130/74	asada, MD Signs Date Wg 4 2/12/12 12 4 12/20/12 9 3/6/12 14 4 2/5/12 13 0 5/10/12 15	t Date LDL 10 8/15/11 14 18 12/20/11 13 14 3/6/12 14 8/15/11 14	Labs L HDL Date 0 60 2/12/ 0 65 12/20/ 0 60 2/12/ 0 60 2/12/	K+ Date /12 3.8 2/12/12 /12 3.5 12/20/12 /12 3.8 2/5/12	Consult Na+ Date / 135 140 135 6/18/12/20 135	Hospitalii Date 12/20/11Arryth 12/20/11Acute 12/20/11Acute	D: thmia <mark>e Mi</mark> te Mi
mes Messink, MD obert Boyne, MD eter Broxon, MD hn Casada, MD sa Gray, MD aren Morale, MD ffery Noggler, MD mothy Shadley, MD laria Vecchia, MD largaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening-Ages 50-69 ** Colorectal Cancer Screening **	 Rate 	System Appointment: Tomorrow T S Tt Boyne Broxon Cesada Iray	3 TC Vext Veek Patie Harrison Hall, Mari	Disease Stage ant Stage th, A 3 dy, J 3 ss, B 3 c, C 2 *, D 4	ents – John C Vital 3 2/12/12 130/7 3/6/11 150/7 2/5/12 130/7 5/10/12 140/90 5 – Benjamin	asada, MD Signs Date Wg 4 2/12/12 12 4 12/20/12 9 3/6/12 14 4 2/5/12 13 0 5/10/12 15	t Date LDL 10 8/15/11 14 18 12/20/11 13 14 3/5/11 14 8/15/11 14 0 5/10/12 20	Labs L HDL Date 0 60 2/12/ 0 65 12/20/ 0 60 2/12/ 0 60 2/12/	Ke Date /12 3.8 2/12/12 /12 3.5 12/20/12 /12 3.4 1/9/12 /12 3.3 4/10/12	Consult Na+ Date / 135 140 135 6/18/12/20 135	Hospitalii Date 12/20/11Arryth 12/20/11Acute 12/20/11Acute	D thmia <mark>e Mi</mark> te Mi
mes Messink, MD obert Boyne, MD trer Broxon, MD hn Casada, MD ia Gray, MD iren Morale, MD ffery Noggler, MD mothy Shadley, MD aria Vecchia, MD argaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening-Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources:	 Rate 	System Appointment Tomorrow T Srs rtBoyne Broxon Cesada iray Norale	3 TC Vext Veek Patie Harrison Hall, Mari	ODAY's Patie Disease ant Stage th, A 3 dy, J 3 s, B 3 c 2 k, D 4 Atient Details Medicati	ents – John C Vital 3 2/12/12 130/7 3/6/11 150/7 2/5/12 130/7 5/10/12 140/90 5 – Benjamin	asada, MD Signs Date Wg 4 2/12/12 12 4 2/20/12 14 4 2/5/12 14 4 2/5/12 14 5 5/10/12 15 Jones	t Date LDL 10 8/15/11 14 18 12/20/11 13 14 3/5/11 14 8/15/11 14 0 5/10/12 20	Labs HDL Date 0 60 2/12/ 0 65 12/20/ 0 60 3/6/ 0 60 3/6/ 0 60 4/10/	Ke Date /12 3.8 2/12/12 /12 3.5 12/20/12 /12 3.4 1/9/12 /12 3.3 4/10/12	Consult Na+ Data / 135 140 135/4/18/12/20 135 128 5/10/12 Re	Hospitali Date 12/20/11 Acute 12/20/11 Acute 12/20/11 Acute	D thmia e MI te MI te Exa
mes Messink, MD obert Boyne, MD trer Broxon, MD hn Casada, MD ia Gray, MD iren Morale, MD ffery Noggler, MD mothy Shadley, MD aria Vecchia, MD argaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System Appointment: Tomorrow T S Tt Boyne Broxon Cesada Iray	s T(Next Veek Patie Smith Hard Mar Patie Patie Smith Hard Mar Patie Smith Smith Hard Mar	DDAY's Patie Disease th, A 3 dy, J 3 dy, J 3 c. 2 k, D 4 atient Details Medicati d Do	ents – John C Vital s Date BP 2/12/12 130/7 3/6/11 150/0 2/5/12 130/7 5/10/12 140/90 s – Benjamin ons	asada, MD ^{Signs} Date Wg 4 2/12/12 12 1 2/20/12 9 3//01/12 15 5/10/12 15 Jones ate	t Date LD1 10 8/15/11 14 18 12/20/11 13 14 37/0/12 14 14 8/15/11 14 10 5/10/12 20 Procedures	Labs HDL Date 0 60 2/12/ 0 65 12/20(0 60 2/12/ 0 60 2/12/ 0 40 4/10/ s/Diagnostics Results	Ke Date /12 3.8 2/12/12 /12 3.5 12/20/12 /12 3.4 1/9/12 /12 3.3 4/10/12	Consult Na+ Date / 135 140 135 135 128 5/10/12 Re Date T	to Date 12/20/11 Arryth 12/20/11 Avryth 12/20/11 Avryth 12/20/	D: thmia te MI te Exac
mes Messink, MD sbert Boyne, MD eter Broxon, MD hn Casada, MD ia Gray, MD iren Morale, MD ffery Noggler, MD mothy Shadley, MD aria Vecchia, MD argaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System Appointment Tomorrow YS rt Boyne Broxon Casada Bray Morale ry Noggier	s Tri Noxt Partie Viext Santie Hart Hart Hart Hart Hart Hart Hart Hart	DDAY's Patie Disease ant Stage th, A 3 dy, J 3 c, C 2 a, D 4 atlent Details Medicati d Dc coppril 20	ents – John C Vital 3 Date BP 2/12/12 130/7 3/0/11 90/7 5/10/12 140/90 3 – Benjamin ons	asada, MD Date Wg 24/12/12 14 12/20/12 9 4 2/5/12 13 5/10/12 15 Jones ate 3/6/2012	t Date LDL 0 8/15/11 14 8 12/20/11 13 4 39/01/21 14 4 8/15/11 14 0 5/10/12 20 Procedure: Proc/Test	Labs HDL Date 0 60 2/12/ 0 65 12/20(0 60 2/12/ 0 60 2/12/ 0 40 4/10/ s/Diagnostics Results	Ke Date 1/12 3.8 2/12/2012 1/12 3.5 12/2012 1/12 3.8 2/15/12 1/12 3.8 2/5/12 1/12 3.8 2/5/12 1/12 3.8 4/10/12 1/12 3.8 4/10/12	Consult Na+ Date / 135 140 135 135 128 5/10/12 Re Date T	to Date 12/20/11 Arryth 12/20/11 Avryth 12/20/11 Avryth 12/20/	Do thmia te MI te Exac
mes Messink, MD obert Boyne, MD eter Broxon, MD shn Casada, MD sa Gray, MD aren Morale, MD (ffery Noggler, MD mothy Shadley, MD laria Vecchia, MD largaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System Appointment: Tomorow T TS Tt Boyne Brown Casada Fra Dr. Timothy Shadley Dr. Maria Vecchia	s Tri Noxt Partie Viext Santie Hart Hart Hart Hart Hart Hart Hart Hart	ODAY's Patie nt Stease th.A 3 th.A 3 th.B 1 C 2 %,D 4 Medicati d De opprol 20 opprol 122	ents – John C Viais Date BP 2/12/12 130(7- 2/12/12 130(7- 2/12/12 130(7- 2/12/12 140)90 B – Benjamin ons sse Di mg daily	asada, MD Date Wg 24/12/12 14 12/20/12 9 4 2/5/12 13 5/10/12 15 Jones ate 3/6/2012	t Date LDL 0 8/15/11 14 8/12/2011 13 4/ 8/15/11 14 4/ 8/15/11 14 0 5/10/12 20 Procedure: Proc/Test 2 (hest Xray	Labs 0 60 2/12/ 0 65 12/00 0 60 2/12/ 0 60 2/12/ 0 60 2/12/ 0 60 2/12/ 0 60 2/12/ 0 40 4/10/ s/Diagnostics Results Enlarged hear	Ke Date 1/12 3.8 2/12/2012 1/12 3.5 12/2012 1/12 3.8 2/15/12 1/12 3.8 2/5/12 1/12 3.8 2/5/12 1/12 3.8 4/10/12 1/12 3.8 4/10/12	Consult Na+ Date / 135 140 135 135 128 5/10/12 Re Date T	to Date 12/20/11 Arryth 12/20/11 Avryth 12/20/11 Avryth 12/20/	D: thmia te MI te Exac
mes Messink, MD obert Boyne, MD eter Broxon, MD yhn Casada, MD sa Gray, MD aren Morale, MD offery Noggler, MD mothy Shadley, MD faria Vecchia, MD fargaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System Appointment Tomorrow TS TBoyne Broxon Essads iray Norale Pr Norgler Dr. Timothy Shadley Dr. Maria Vecchia Historical Trends	s T(sect Veck Veck Hall Mar Pat Lisin Met Lisin	ODAY's Patie nt Stease th.A 3 th.A 3 th.B 1 C 2 %,D 4 Medicati d De opprol 20 opprol 122	ents – John C Viral 3 2020 8 87 21/2/12 1307/7012 21/2/12 1307 21/2/12 1307 21/2/12 140/99 3 – Benjamin ons 5 – Benjamin ons 5 – Benjamin 5 – Benjamin 5 – Benjamin 5 – Benjamin 5 – Benjamin 5 – Benjamin	asada, MD Date Wg 24/12/12 14 12/20/12 9 4 2/5/12 13 5/10/12 15 Jones ate 3/6/2012	t Date LDL 0 8/15/11 14 8/12/2011 13 4/ 8/15/11 14 4/ 8/15/11 14 0 5/10/12 20 Procedure: Proc/Test 2 (hest Xray	Labs 0 60 2/12/ 0 65 12/00 0 60 2/12/ 0 60 2/12/ 0 60 2/12/ 0 60 2/12/ 0 60 2/12/ 0 40 4/10/ s/Diagnostics Results Enlarged hear	Ke Date 1/12 3.8 2/12/2012 1/12 3.5 12/2012 1/12 3.8 2/15/12 1/12 3.8 2/5/12 1/12 3.8 2/5/12 1/12 3.8 4/10/12 1/12 3.8 4/10/12	Consult Na+ Date / 135 140 135 135 128 5/10/12 Re Date T	to Date 12/20/11 Arryth 12/20/11 Avryth 12/20/11 Avryth 12/20/	Do thmia te MI te Exac
ames Messink, MD lobert Boyne, MD leter Broxon, MD ohn Casada, MD lsa Gray, MD daren Morale, MD effery Noggler, MD imothy Shadley, MD Aaria Vecchia, MD Aargaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System	s T(lext Veek Hall Mar Patient Hall Mar Lisin Met	ODAY's Patie nt Stease th.A 3 th.A 3 th.B 1 C 2 %,D 4 Medicati d De opprol 20 opprol 122	Porte BP 2/12/12 130/7-12 2/12/12 130/7-12 2/12/12 130/7-12 2/12/12 130/7-12 2/12/12 130/7-12 2/12/12 130/7-12 2/12/12 140/76 5/10/12 140/76 5- Benjamin ons orse D4 5 mg daily mg daily	asada, MD ^{Signs} Date We 4 2/12/12 12 5/10/12 15 5/10/12 15 Jones ste 3/6/2012 5/22/2012	t Date LDL 0 8/15/11 14 8/12/2011 13 4/ 8/15/11 14 4/ 8/15/11 14 0 5/10/12 20 Procedure: Proc/Test 2 (hest Xray	Labs HDL Dete 0 0	Ke Date 1/12 3.8 2/12/20/12 1/12 3.5 12/20/12 1/12 3.8 2/5/12 1/12 3.8 2/5/12 1/12 3.8 4/10/12 1/12 3.8 4/10/12 1/12 3.8 4/10/12	Consult Na+ Date / 135 140 135 136 137 137 137 137 137 137 137 137 137 137	to Date 12/20/11 Arryth 12/20/11 Avryth 12/20/11 Avryth 12/20/	Dx thmia e Mi te Mi te Exace
Providers lames Messink, MD Robert Boyne, MD Peter Broxon, MD John Casada, MD Asa Gray, MD (aren Morale, MD leffery Noggler, MD Timothy Shadley, MD Marja Vecchia, MD Margaret Sign, MD Julio Garzia, MD, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System Appointment Tomorrow TS TBoyne Broxon Essads iray Norale Pr Norgler Dr. Timothy Shadley Dr. Maria Vecchia Historical Trends	s Tr iext iext Fact Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Patient Hall Mar Hall H	DDAY's Patie nt Stage th, A 3 dy, J 3 th, B 2 c, 2 attent Details Medicati d Do oprolol 12: x 10 reventive/Rit	ents – John C Vial 3 Dote 8 27/21/21 3007- 12/2011 9077- 27/912 19077- 57/10/21 19079 57/10/21 19079 57/10/210/2100000000000000000000000000000	asada, MD Signs Date Wg 4 2/12/12 12 12/2012 4 2/5/12 13 5/10/12 15 Jones ste 3/6/2012	t Dete LDL 0 8(75)11 14 4 8(75)11 14 4 8(75)11 14 0 5/10/12 20 Procedure: Proc/Test 2 Chest Xray 2 Cardiac Cath Education I	Labs HDL Date 0 60 2/12/2 0 65 2/12/2 0 64 4/10/ s/Diagnostics Results Enlarged hear 2 vessel disea Measures Measures	K+ Data 1/12 3.8 2/12/12 1/2 3.5 2/2/02 1/2 3.5 2/2/02 1/2 3.5 2/12/02 1/2 3.5 2/12/02 1/2 3.5 4/10/12 1/2 1/2 3.5 1/2 3.5 4/10/12 1/2 3.5 4/10/12	Consult Ne+ Date / 135 135 135 138 5/10/12Re Date T n 6/18/2012 C	to Dee 12/20/11Arry10	Dx thmia e MI te Exact sults ding
ames Messink, MD Robert Boyne, MD Peter Broxon, MD ohn Casada, MD Asa Gray, MD Garan Morale, MD effery Noggler, MD Timothy Shadley, MD Vlaria Vecchia, MD Vlargaret Sign, MD	Blood Pressure Control <140/90 ** Optimal Diabetes Care Combination 1 - LDL<100, HbA1c<8.0%, Nephropathy Monitoring Prevention Childhood Immunization Status-24-mo Continuous Enrollment: Combination of all Antigens ** Immunization for Adolescents-Combination of Tdap and meningococcal ** Chlamydia Screening in Women-Ages 16-24 ** Evidence-based Cervical Cancer Screening-Appropriately Screened ** Breast Cancer Screening -Ages 50-69 ** Colorectal Cancer Screening ** ** CQM measure in the CMS EHR Incentive Program (MU) for Eligible Professionals Measure Sources: ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults with Heart Failure	 Rate 	System Appointment Tomorrow Ts	s TG lext Veek Hall Har Hall Hall	ODAY's Patie ant Stage th, A 3 th, A 3 th, C 2 x, D 4 atient Details Medicati d Dc oprolol 222 x 10	ents – John C Vial 3 Dote 8 27/21/21 3007- 12/2011 9077- 27/912 19077- 57/10/21 19079 57/10/21 19079 57/10/210/2100000000000000000000000000000	asada, MD Figns Dete Wg 4 (21/21/2) 12 1 (22/01/2) 9 4 (2/5/12) 13 5/10/12 15 Jones tte 3/6/2017 5/22/2011	Date LDL 08/15/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 14 16/17/11 16/17	Labs HDL Dete 0 00 2/12/ 0 00 2/12/ 0 00 2/12/ 0 00 2/12/ 0 00 2/12/ 0 00 2/12/ 0 00 2/12/ 1/00 0 00 2/12/ 0 2/12/ 0 00 2/12/ 0 2/12/ 0 00 2/12/ 0 2/12/ 0 00 2/12/ 0 2/12/1/ 0 2/12/	Ke Date 1/12 3.8 2/12/12 1/12 3.8 2/12/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/12 3.8 2/13/12 1/14 1/14/12 3.8 1/14 1/14/12 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 1/14/14 1/14/14 1/14 <td>Consult 135 135 135 135 135 135 135 135</td> <td>D Dite 12/2011Avate 12/2011Avat</td> <td>Dx thmia e MI te Exaco sults ding re</td>	Consult 135 135 135 135 135 135 135 135	D Dite 12/2011Avate 12/2011Avat	Dx thmia e MI te Exaco sults ding re

... to improve performance and quality


Preventive Measures Education Recommended Care Smoking cessation

Weight instruction

12 CSOHIMSS 2013 Slide 12

May 17th, 2013

Information-based Performance Improvement...




HUMSS Central & Southern Ohio Chapter IHA

...Leads to ...






Health Analytics Maturity Model




Himss

Central & Southern Ohio Chapter



Anatomy of a Data Element – From Source to Re-purpose




Himss

Central & Southern Ohio Chapter

Meaningful Use: The Practical Approach







Data governance makes sure data gets from May 17th, 2013 Slide 18

10

Reading Contraction Pleading Approximates

Multi-dimensional Assessment and Plan

Central & Southern Ohio Chapter

Dimensions

1) Organizational Alignment

- Enterprise-level strategy
- Alignment of Business / IT strategic goals

2) Information Culture

3) Clinical Integration


- Enterprise-level workflow optimization
- Cross-continuum care coordination
- External community linkages
- Patient-Centric Care

© CSOHIMSS 2013 Slide 19

4) Front-End Integration

5) Health Information Exchange 6) BI / Analytics

7) Core Systems Environment







A CASE STUDY






Meaningful Use: The Practical Approach








© CSOHIMSS 2013 Slide 21

May 17th, 2013

Meaningful Use: The Practical Approach

Based on an eMeasure foundation


HINSS Central & Southern Ohio Chapter



Driving performance improvement: A Meaningful Use Dashboard




Cognos Viewer - Dashboard						Boberg, Carol Log Off 🛉 🔒 About					
				🔁 Кеер	o this version 🔻 🕨 🎼	🐁 👪 🕶 🐻 🕶 🌁 Add this report 🕶 📐					
	Meaningful Use Dashbo		liance	Te	епет						
Measures Summary Measures Analysis Co	QM Analysis										
Choose a Facility	Utilization Measures - Cur	rent Repor	ting Period - as	s of Oct 6, 2010							
€ Grporate	Hospital Name	C	ore Set	Menu Set	Days Reporting						
	DES PERES HOSPITAL	9	5	9	1 35						
	DESERT REGIONAL MEDICAL CENTER	8	6	7 3	35						
	JFK MEMORIAL HOSPITAL	11	3	8	2 35						
	PLACENTIA LINDA HOSPITAL	10	4	8	2 5						
	SAN RAMON REGIONAL MEDICAL CTR	10	4	3 7	5						
	SIERRA VISTA REGIONAL MED CTR	9	5	4 6	5						
	TWIN CITIES COMMUNITY HOSPITAL	11	3	3 7	5						
Deselect all		1									
Stage			 Able 	to identify ar	reas of risk	in a timely					
Stage One											
			man	ner and test F	process						
Fiscal Year Submission			data								
2012			<u> </u>								
Submit			Conduct root cause analysis								
			Carry out improvement through training,								
						-					
			com	munication, p	ange and/or						
12-Jan-2011			cycty	omfix							
43				em fix							
CSOHIMSS 2013 Slide 23			way 17", 2013		Wea	aningrui Use: The Practical Approach					



The New Fundamentals





© CSOHIMSS 2013 Slide 25

May 17th, 2013

Meaningful Use: The Practical Approach



References:

White Paper: A World Evolving Toward Value Video: eMeasures

http://www.encorehealthresources.com/




rthomas@encorehealthresources.com

beckert@encorehealthresources.com

MU is the foundation for clinical eMeasures ...





... and using EHR data for reporting

Agenda

